The study of therapeutic effect and safety of Paracetamoland Tramadol Hydrochloride on patient with chronic pain

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-14004913

Enrollment

Unknown

Registered

2014-07-08

Start date

2014-07-08

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain

Interventions

Test group:Paracetamoland Tramadol Hydrochloride

Control:Paracetamoland Tramadol Hydrochloride

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age 18-65 years old, both male and female, patient with Moderate to severe pain (VAS more than 4), informed consent been signed.

Exclusion criteria

Exclusion criteria: 1.Participating in other clinical trials within four weeks; Patients who suffer severe organic disease (serious liver or kidney disease, NYHA more than III class, etc.); Patient with respiratory depression, airway obstruction, tissue hypoxia, history of asthma, severe intracranial hypertension, cerebral hernia and coma; lactating and pregnant women; Patients have psychonosema; Volunteers who are using central analgesic medications. Opiate addiction, and dependence.

Design outcomes

Primary

Measure	Time frame
VAS;Pain's effect on sleepness;Nausea and vomiting;Fatigu;	—

Contacts

Public ContactWang Baoguo

wbgttyy@163.com+86 13370185075

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026